pneumocystis carinii

(redirected from pneumocystis)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

pneumocystis carinii:

see pneumoniapneumonia
, acute infection of one or both lungs that can be caused by a bacterium, usually Streptococcus pneumoniae (also called pneumococcus; see streptococcus), or by a virus, fungus, or other organism.
..... Click the link for more information.
References in periodicals archive ?
We defined confirmed PCP as a positive result for Pneumocystis jirovecii by Gomori-Grocott or toluidine blue stain or positive immunofluorescence test results (4) for a bronchoalveolar lavage (BAL) fluid or induced sputum specimen.
Autopsy findings suggest that dissemination of Pneumocystis may occur via direct spread, hematogenous spread, or via lymphatic vessels.
Pneumocystis pneumonia is still one of the most common opportunistic infections found in patients infected with HIV.
Imaging features of Pneumocystis carinii pneumonia.
A New Name (Pneumocystis jiroveci) for Pneumocystis from humans.
This new test from Myconostica will allow healthcare professionals to rapidly identify those patients infected by Aspergillus or Pneumocystis thus enabling clinicians to prescribe appropriate drugs to treat the infection.
Immtech has advanced clinical programs that include new oral treatments for Pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (African sleeping sickness), and a well defined, expanding library of compounds targeting Hepatitis C, fungal infections, and bacterial infections.
In the blinded study, investigators compared quantitative touch-down polymerase chain reaction (QTD PCR) results with bronchoscopy with bronchoalveolar lavage (BAL), which is widely considered to be the standard for the diagnosis of Pneumocystis pneumonia (PCP).
Atovaquone is marketed in the United States under the trade name Mepron for Pneumocystis carinii pneumonia.
Other reported pathogens are mycobacteria, fungi, Pneumocystis carinii, Escherichia coli, and Salmonella typhimurium.
Vernon Hills, IL, announced its first pharmaceutical product, DB-289, for the treatment of Pneumocystis carinii pneumonia (PCP and Trypanosomiasis, is set to begin human clinical trials in the third quarter of 2000.
Approved November 25, 1992 for the treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in patients who are intolerant to Bactrim or Septra.